Announcement on Sawai Organizational and Personnel Changes
Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018.
- OrganizationalChanges
“Development QA” is renamed “QA Department”.
※The purpose of the QA Department is to integrate and strengthen the quality assurance (QA) function within the Research and Development division.
- PersonnelChanges
- Executive officer (Effective April 1,2018)
| Name | New Post | Current Post |
| Kyozo Inari | Executive Officer
Supervisor of External Affairs Department |
Executive Officer
General Manager of External Affairs Department |
- General Managers (Effective April 1,2018)
| Name | New Post | Current Post |
| Yoshiomi Kunihiro | General Manager of External Affairs Department | Executive Specialist of External Affairs |
| Tooru Shinki | General Manager of Sapporo Branch | Manager of Sales Section, Tokyo Daini Branch |
| Yoshiki Ozawa | General Manager of Development Department | Group Manager of Regulatory Affairs Group, Development Department |
| Hiromu Toyoda | General Manager of QA Department | General Manager of Development QA |
About Sawai
Founded in 1929, Sawai Pharmaceutical Co., Ltd. has grown into one of the leading generics companies in Japan. Guided by its corporate philosophy, “Patients First,” Sawai markets more than 700 high-quality generic products and reliably delivers them to patients throughout Japan. In 2017, Sawai acquired US-based Upsher-Smith Laboratories, LLC marking its first step in overseas expansion to become a globally recognized generic pharmaceutical company. For more information, visit: https://www.sawai.co.jp/en/.
For further information please contact:
PR/IR group, pr@sawai.co.jp